Advanced search
1 file | 325.72 KB Add to list

Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment : results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)

(2019) OSTEOPOROSIS INTERNATIONAL. 30(11). p.2155-2165
Author
Organization
Abstract
A Summary Many patients at increased risk of fractures do not take their medication appropriately, resulting in a substantial decrease in the benefits of drug therapy. Improving medication adherence is urgently needed but remains laborious, given the numerous and multidimensional reasons for non-adherence, suggesting the need for measurement-guided, multifactorial and individualized solutions. Introduction Poor adherence to medications is a major challenge in the treatment of osteoporosis. This paper aimed to provide an overview of the consequences, determinants and potential solutions to poor adherence and persistence to osteoporosis medication. Methods A working group was organized by the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal diseases (ESCEO) to review consequences, determinants and potential solutions to adherence and to make recommendations for practice and further research. A systematic literature review and a face-to-face experts meeting were undertaken. Results Medication non-adherence is associated with increased risk of fractures, leading to a substantial decrease in the clinical and economic benefits of drug therapy. Reasons for non-adherence are numerous and multidimensional for each patient, depending on the interplay of multiple factors, suggesting the need for multifactorial and individualized solutions. Few interventions have been shown to improve adherence or persistence to osteoporosis treatment. Promising actions include patient education with counselling, adherence monitoring with feedback and dose simplification including flexible dosing regimen. Recommendations for practice and further research were also provided. To adequately manage adherence, it is important to (1) understand the problem (initiation, implementation and/or persistence), (2) to measure adherence and (3) to identify the reason of non-adherence and fix it. Conclusion These recommendations are intended for clinicians to manage adherence of their patients and to researchers and policy makers to design, facilitate and appropriately use adherence interventions.
Keywords
Adherence, Determinants, Osteoporosis, Persistence, Solutions, SHARED DECISION-MAKING, MEDICATION ADHERENCE, FRACTURE RISK, POSTMENOPAUSAL WOMEN, PERSISTENCE, CARE, PATIENT, INTERVENTIONS, BISPHOSPHONATES, NONADHERENCE

Downloads

  • Hiligsmann2019 Article DeterminantsConsequencesAndPot.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 325.72 KB

Citation

Please use this url to cite or link to this publication:

MLA
Hiligsmann, M., et al. “Determinants, Consequences and Potential Solutions to Poor Adherence to Anti-Osteoporosis Treatment : Results of an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF).” OSTEOPOROSIS INTERNATIONAL, vol. 30, no. 11, 2019, pp. 2155–65, doi:10.1007/s00198-019-05104-5.
APA
Hiligsmann, M., Cornelissen, D., Vrijens, B., Abrahamsen, B., Al-Daghri, N., Biver, E., … Reginster, J. Y. (2019). Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment : results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). OSTEOPOROSIS INTERNATIONAL, 30(11), 2155–2165. https://doi.org/10.1007/s00198-019-05104-5
Chicago author-date
Hiligsmann, M., D. Cornelissen, B. Vrijens, B. Abrahamsen, N. Al-Daghri, E. Biver, M. L. Brandi, et al. 2019. “Determinants, Consequences and Potential Solutions to Poor Adherence to Anti-Osteoporosis Treatment : Results of an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF).” OSTEOPOROSIS INTERNATIONAL 30 (11): 2155–65. https://doi.org/10.1007/s00198-019-05104-5.
Chicago author-date (all authors)
Hiligsmann, M., D. Cornelissen, B. Vrijens, B. Abrahamsen, N. Al-Daghri, E. Biver, M. L. Brandi, O. Bruyere, N. Burlet, C. Cooper, B. Cortet, E. Dennison, A. Diez-Perez, A. Gasparik, A. Grosso, P. Hadji, P. Halbout, J. A. Kanis, Jean Kaufman, A. Laslop, S. Maggi, R. Rizzoli, T. Thomas, S. Tuzun, M. Vlaskovska, and J. Y. Reginster. 2019. “Determinants, Consequences and Potential Solutions to Poor Adherence to Anti-Osteoporosis Treatment : Results of an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF).” OSTEOPOROSIS INTERNATIONAL 30 (11): 2155–2165. doi:10.1007/s00198-019-05104-5.
Vancouver
1.
Hiligsmann M, Cornelissen D, Vrijens B, Abrahamsen B, Al-Daghri N, Biver E, et al. Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment : results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). OSTEOPOROSIS INTERNATIONAL. 2019;30(11):2155–65.
IEEE
[1]
M. Hiligsmann et al., “Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment : results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF),” OSTEOPOROSIS INTERNATIONAL, vol. 30, no. 11, pp. 2155–2165, 2019.
@article{8698878,
  abstract     = {{A Summary Many patients at increased risk of fractures do not take their medication appropriately, resulting in a substantial decrease in the benefits of drug therapy. Improving medication adherence is urgently needed but remains laborious, given the numerous and multidimensional reasons for non-adherence, suggesting the need for measurement-guided, multifactorial and individualized solutions. Introduction Poor adherence to medications is a major challenge in the treatment of osteoporosis. This paper aimed to provide an overview of the consequences, determinants and potential solutions to poor adherence and persistence to osteoporosis medication. Methods A working group was organized by the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal diseases (ESCEO) to review consequences, determinants and potential solutions to adherence and to make recommendations for practice and further research. A systematic literature review and a face-to-face experts meeting were undertaken. Results Medication non-adherence is associated with increased risk of fractures, leading to a substantial decrease in the clinical and economic benefits of drug therapy. Reasons for non-adherence are numerous and multidimensional for each patient, depending on the interplay of multiple factors, suggesting the need for multifactorial and individualized solutions. Few interventions have been shown to improve adherence or persistence to osteoporosis treatment. Promising actions include patient education with counselling, adherence monitoring with feedback and dose simplification including flexible dosing regimen. Recommendations for practice and further research were also provided. To adequately manage adherence, it is important to (1) understand the problem (initiation, implementation and/or persistence), (2) to measure adherence and (3) to identify the reason of non-adherence and fix it. Conclusion These recommendations are intended for clinicians to manage adherence of their patients and to researchers and policy makers to design, facilitate and appropriately use adherence interventions.}},
  author       = {{Hiligsmann, M. and Cornelissen, D. and Vrijens, B. and Abrahamsen, B. and Al-Daghri, N. and Biver, E. and Brandi, M. L. and Bruyere, O. and Burlet, N. and Cooper, C. and Cortet, B. and Dennison, E. and Diez-Perez, A. and Gasparik, A. and Grosso, A. and Hadji, P. and Halbout, P. and Kanis, J. A. and Kaufman, Jean and Laslop, A. and Maggi, S. and Rizzoli, R. and Thomas, T. and Tuzun, S. and Vlaskovska, M. and Reginster, J. Y.}},
  issn         = {{0937-941X}},
  journal      = {{OSTEOPOROSIS INTERNATIONAL}},
  keywords     = {{Adherence,Determinants,Osteoporosis,Persistence,Solutions,SHARED DECISION-MAKING,MEDICATION ADHERENCE,FRACTURE RISK,POSTMENOPAUSAL WOMEN,PERSISTENCE,CARE,PATIENT,INTERVENTIONS,BISPHOSPHONATES,NONADHERENCE}},
  language     = {{eng}},
  number       = {{11}},
  pages        = {{2155--2165}},
  title        = {{Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment : results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)}},
  url          = {{http://dx.doi.org/10.1007/s00198-019-05104-5}},
  volume       = {{30}},
  year         = {{2019}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: